BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy.
Chemical | |
---|---|
CAS Num | 1395051-72-5 |
Chemical Formula | C29H34N8O3 |
Molecular Weight | 542.63206 |
IUPAC Chemical Name | N-(3-(4-((3-(5-ethylisoxazol-3-yl)ureido)methyl)phenyl)-1H-pyrazol-5-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide |
Exact Mass | 542.27539 |
Elemental Analysis | C, 64.19; H, 6.32; N, 20.65; O, 8.85 |
Synonym | BPR1J340; BPR1J 340; BPR1J-340. |
Solubility | Soluble in DMSO, not in water |
SMILES Code | O=C(NC1=CC(C2=CC=C(CNC(NC3=NOC(CC)=C3)=O)C=C2)=NN1)C4=CC=C(CN5CCN(C)CC5)C=C4 |
Biological | |
Targets and Effects | FLT3 inhibitor |
Pathways | Apoptosis |
Physical | |
Appearance | white solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Shelf Life | >2 years if stored properly |
Anba Pharma Company
3-H Gill Street, Suite 300
Woburn, MA 01801
United State
Tel: 1+610-883-0668
Email: sales@AnbaPharma.com